Wortmannin

Human SDF1α was purchased from PeproTech; UK14304, rapamycin, brefeldin A, monensin, nigericin, swainsonine, and Exo2 were from Sigma–Aldrich; pertussis toxin was from List Biological Laboratories; gallein was from Tocris Bioscience; wortmannin, AS-604850, and GSK2292767 were from ApexBio; TGX-221 and HS-173 were from Adooq Bioscience; secinH3, GCA, nocodazole, ilimaquinone, AMD3100, control siRNA, and siRNA targeting human ARF1, CRISPR–Cas9 control plasmids, and knockout plasmids targeting human ARF1, and antibodies against phospho-ERK1/2 and β-actin were from Santa Cruz Biotechnology; p230 antibodies were from BD Transduction Laboratories; ARF1 antibodies were purchased from Abcam; ERK1/2 antibodies were from Cell Signaling Technology; 12-well inserts and Matrigel matrix were from Corning. All other materials were obtained as described elsewhere (9 (link), 19 (link), 27 (link)).

Human SDF1α was purchased from PeproTech; UK14304, GW5074, rapamycin, BFA, ilimaquinone, monensin, nigericin, swainsonine, and LY294002 were from Sigma Aldrich; nocodazole, insulin-like growth factor 1, AMD3100, control siRNA (medium GC), siRNAs targeting to human PI3Kγ regulatory subunits p101 and p87, and antibodies against GFP, phospho-ERK1/2, Gγ9, and β-actin and the PI3Kγ subunits p110γ, p101 and p87 were from Santa Cruz Biotechnology; wortmannin, AS-604850, and GSK2292767 were from ApexBio; TGX-221 and HS-173 were from Adooq Bioscience; U0126 and PD98059 were from Calbiochem; EGF, puromycin, and blasticidin S were from Thermo Fisher Scientific; U-73122 and AZD5363 were from MedChemExpress; U-73433, CRT0066101, and Go6976 were from Cayman Chemical; PTX was from List Biological Laboratories; gallein and rauwolscine were from Tocris Bioscience; D-Luciferin was from GoldBio; antibodies against hemagglutinin and ERK1/2 were from Cell Signaling Technology; antibodies against Gγ3 were from Abcam. All other materials were obtained as described (52 (link), 53 (link)).